Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide in Non-cirrhotic Non-alcoholic Steatohepatitis
NCT04822181Phase 3Active, not recruiting
- Sponsor
- Novo Nordisk
- Start
- Apr 2021
- Primary completion
- Apr 2029
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 39
01
Overview
A Phase 3 trial of semaglutide in Nonalcoholic steatohepatitis (NASH), sponsored by Novo Nordisk. Started Apr 2021; status: active, not recruiting.
02
Drugs
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT04822181.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04822181.